Literature DB >> 21840181

Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus.

Diixa Patel1, Mashkur Husain, Celine Vidaillac, Molly E Steed, Michael J Rybak, Susan M Seo, Glenn W Kaatz.   

Abstract

Daptomycin is highly active against Staphylococcus aureus, including multidrug-resistant strains and those with reduced susceptibility to vancomycin. However, daptomycin-non-susceptible (Dap(NS)) strains [minimum inhibitory concentration (MIC) >1mg/L] have been derived clinically and in vitro. The mechanism(s) by which this occurs is incompletely understood, but existing data indicate that it is multifactorial. Dap(NS) derivatives of one laboratory and three clinical strains of S. aureus produced using gradient plates were evaluated. The Dap(NS) phenotype included increases in glycopeptide and nisin MICs and in some instances defective autolysis and reduced susceptibility to lysostaphin lysis. Amino acid substitutions in MprF, YycG (WalK), or both, were identified in all Dap(NS) strains. Reduced cytochrome c binding and ability of daptomycin to depolarise whole cells correlated with the Dap(NS) phenotype, consistent with an increase in cell surface positivity. Gene expression data revealed increased expression of vraS, one member of a two-component system involved in the regulation of cell wall biosynthesis, in three of five Dap(NS) strains. The pathway to the Dap(NS) phenotype is not linear, as variable genetic and phenotypic changes may result in identical increases in MICs. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840181     DOI: 10.1016/j.ijantimicag.2011.06.010

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  21 in total

1.  Solid-phase synthesis of fusaricidin/LI-F class of cyclic lipopeptides: Guanidinylation of resin-bound peptidyl amines.

Authors:  Nina Bionda; Jean-Philippe Pitteloud; Predrag Cudic
Journal:  Biopolymers       Date:  2013-04       Impact factor: 2.505

2.  Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics.

Authors:  Andrew D Berti; Justine E Wergin; Gary G Girdaukas; Scott J Hetzel; George Sakoulas; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

3.  VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.

Authors:  Shrenik Mehta; Arabela X Cuirolo; Konrad B Plata; Sarah Riosa; Jared A Silverman; Aileen Rubio; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

4.  A novel point mutation promotes growth phase-dependent daptomycin tolerance in Staphylococcus aureus.

Authors:  Lukas Mechler; Alexander Herbig; Kerstin Paprotka; Martin Fraunholz; Kay Nieselt; Ralph Bertram
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

5.  Heterogeneity of genetic pathways toward daptomycin nonsusceptibility in Staphylococcus aureus determined by adjunctive antibiotics.

Authors:  Andrew D Berti; Sarah L Baines; Benjamin P Howden; George Sakoulas; Victor Nizet; Richard A Proctor; Warren E Rose
Journal:  Antimicrob Agents Chemother       Date:  2015-03-02       Impact factor: 5.191

Review 6.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 7.  Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.

Authors:  Arnold S Bayer; Tanja Schneider; Hans-Georg Sahl
Journal:  Ann N Y Acad Sci       Date:  2012-12-05       Impact factor: 5.691

8.  Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.

Authors:  Warren E Rose; Lucas T Schulz; David Andes; Rob Striker; Andrew D Berti; Paul R Hutson; Sanjay K Shukla
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

9.  Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.

Authors:  Adam Belley; Francis F Arhin; Ingrid Sarmiento; Hong Deng; Warren Rose; Greg Moeck
Journal:  Antimicrob Agents Chemother       Date:  2012-10-22       Impact factor: 5.191

10.  Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.

Authors:  Yang Song; Aileen Rubio; Radheshyam K Jayaswal; Jared A Silverman; Brian J Wilkinson
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.